FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of January 2024 we identify the following current VC trends in the United States: 

  1. Total Healthcare & Life Sciences funding has reached EUR 2,239m, lagging behind January of last year (EUR 2,239m vs EUR 3,330m) 📉
  2. Biotech received 60% of the total investment volume (EUR 1,336m) with oncology being the leading indication(27%)
  3. In January Cellanome secures the highest transaction volume with EUR 137m, followed by Eyconis with EUR 137m and Sudo Biosciences with EUR 135m
  4. Premji Invest (United States) is the most active investor (by deal volume), followed by Novo Holdings (Denmark) and Venrock (United States)

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link.